Health & Medicine | May 22, 2026 | 10 min read | By Bryan White

The 2026 Bundibugyo Emergency: A Rare Ebola Strain Surges in Central Africa

Biology * Public Health * DNA

Introduction: The 2026 Bundibugyo Filovirus Emergency

Declared in May 2026 and escalating through mid-November 2026 into the largest Bundibugyo Ebola epidemic on record, an expanding Ebola virus disease emergency in the Democratic Republic of the Congo (DRC) triggered cross-border introductions into Uganda, Kenya, and Nigeria.[1][2][3] Unlike most recent filovirus outbreaks driven by Orthoebolavirus zairense (Zaire ebolavirus), this epidemiological crisis is caused by Orthoebolavirus bundibugyoense (Bundibugyo virus, BDBV), for which no regulatory-approved vaccines or targeted therapeutics existed at onset.[2][4]

Prompted by this therapeutic void, regional armed conflict, and weeks of undetected circulation, the World Health Organization declared a Public Health Emergency of International Concern on May 17, 2026, followed on May 18 by an Africa CDC Public Health Emergency of Continental Security.[1][5] Representing the DRC's seventeenth Ebola outbreak since 1976, it is only the third documented emergence of the Bundibugyo strain (following 2007 in Uganda and 2012 in the DRC), which historically carried a 25-50 percent case fatality rate.[1][3]

Epidemiological Architecture, Geopolitics, and Diagnostic Blind Spots

Centered initially in Ituri Province, DRC, hemorrhagic clusters appeared in early May 2026 among healthcare workers and artisanal miners in Mongbwalu and Rwampara following zoonotic spillover.[1][4][6] By late November 2026, transmission had expanded across eight DRC provinces -- Ituri (8,028 confirmed cases across 28 of 36 health zones), North Kivu, South Kivu, Tshopo, Haut-U l , Bas-U l , South Ubangi, and North Ubangi -- reaching 11,762 laboratory-confirmed cases, 5,775 deaths (~49.1% crude case fatality ratio), and 3,240 recoveries as of November 20, 2026.[1][2][7] While neighboring Uganda recorded 20 confirmed cases (2 deaths) before WHO and Uganda's Ministry of Health declared its outbreak ended on August 27, 2026, travel-linked introductions later occurred in Kenya (9 confirmed cases, 2 deaths, contained in October 2026) and Nigeria (1 imported case in Abuja evacuated to Switzerland in late October 2026 with no secondary spread).[1][3][7]

| Jurisdiction | | Reported Cases (as of Nov 2026) | | Reported Deaths | | Current Epidemiological Status | | Geographic Zones Affected |

| Democratic Republic of the Congo | | 11,762 confirmed (Nov 20, 2026) | | 5,775 (~49.1% CFR) | | Ongoing community transmission (3,240 recoveries) | | Ituri, North Kivu, South Kivu, Tshopo, Haut-U l , Bas-U l , South & North Ubangi |

| Uganda | | 20 confirmed | | 2 | | Outbreak declared ended (Aug 27, 2026) | | Kampala & border corridors |

| Kenya | | 9 confirmed | | 2 | | Contained (no community transmission) | | Travel-linked cluster (Oct 2026) |

| Nigeria / International | | 1 imported | | 0 | | Contained (evacuated to Switzerland Oct 26, 2026) | | Abuja (evacuated to Switzerland) |

Early in the DRC surge, roughly two-thirds of confirmed cases were women, alongside disproportionate rates in adults aged 20-39 and frontline clinicians.[3][8] Under Kermack-McKendrick transmission dynamics, the effective basic reproduction number was amplified by armed insurgency, nearly one million displaced people in unsanitary Ituri camps, disrupted community health networks, and political mistrust -- exemplified at Rwampara General Hospital near Bunia, where rioters protesting a safe burial burned two ALIMA isolation tents.[1][4][9]

Early detection was crippled because rural clinics used stockpiled reverse-transcription polymerase chain reaction (RT-PCR) primers specific to Zaire ebolavirus, producing false-negative tests and nosocomial amplification before genomic sequencing confirmed the Bundibugyo strain.[4][6]

| Diagnostic Challenge | | Underlying Cause | | Epidemiological Consequence |

| False Negatives (Early May) | | Reliance on Zaire-specific PCR primer sets.[4] | | Missed cases, nosocomial amplification, delayed outbreak declaration.[4] |

| Testing Backlogs | | Initial global shortage of Bundibugyo-specific assay kits.[4] | | Delayed contact tracing, reliance on clinical presumptive diagnosis, inability to clear suspect wards.[4] |

| Clinical Misdiagnosis | | Symptom overlap with endemic malaria, typhoid, and seasonal influenza.[1] | | Community resistance to Ebola protocols, unsafe burial of unrecognized victims.[1] |

Molecular Virology, Glycoprotein Editing, and Genomic Drift

Examining the molecular biology of Filoviridae shows that BDBV is an enveloped, filamentous, negative-sense single-stranded RNA virus (~805 x 97 nm) whose ~19-kb genome of nucleotides encodes seven proteins: NP, VP35, VP40, GP, VP30, VP24, and the RNA-dependent RNA polymerase (L).[10][11][12] During transcription, co-transcriptional RNA editing of the GP gene yields three products: unedited messenger RNA produces secreted glycoprotein (sGP) to decoy host neutralizing antibodies; a secondary transcript yields small soluble glycoprotein (ssGP); and non-templated adenosine insertion produces the trimeric structural spike (GP1/GP2).[10][13][14] After macropinocytosis into the cytoplasm, endosomal cathepsins cleave the GP1 glycan cap to expose the Niemann-Pick C1 (NPC1) receptor-binding pocket, triggering GP2-driven membrane fusion.[14][15][16]

| Glycoprotein Variant | | Transcriptional Origin | | Structural Function and Pathogenic Role |

| Secreted Glycoprotein (sGP) | | Primary unedited transcript | | Secreted abundantly into blood; acts as an immunological decoy to absorb host antibodies.[10] |

| Small Soluble Glycoprotein (ssGP) | | Secondary edited transcript | | Forms a 100

kDa homodimer; specific pathogenic mechanisms currently under investigation.[13] |

| Structural Glycoprotein (GP) | | Edited transcript (adenosine insertion) | | Forms trimeric surface spikes; mediates endosomal entry, receptor binding, and membrane fusion.[14] |

Genomic comparisons of BDBV isolates highlight substitutions across untranslated and polymerase-associated regions that regulate viral replication kinetics.[17][18] Despite ongoing genetic drift and mutation, BDBV has not evolved airborne transmission and remains an obligate bodily-fluid contact pathogen causing cytokine storms, endothelial coagulopathy, and hypovolemic shock.[1][6][18]

Pan-Ebolavirus Immunotherapeutics, Antivirals, and Vaccines

Because Bundibugyo and Zaire glycoproteins differ by up to 40 percent in amino acid sequence, Zaire-specific biologics (Inmazeb, Ebanga, Ervebo) fail against BDBV.[1][19] Emergency clinical evaluation through the WHO- and INRB-led PARTNERS therapeutic trial (launched in July 2026) centers on pan-ebolavirus biologics, including Mapp Biopharmaceutical's BARDA-backed cocktail MBP134 (comprising survivor-derived antibodies ADI-15878 and ADI-23774), its afucosylated NK-recruiting variant MBP134AF, and its intramuscular half-life-extended formulation MBP431.[20][21][22][23][24]

| Monoclonal Antibody Candidate | | Target Epitope on Glycoprotein | | Mechanism of Action | | Clinical Advantage |

| ADI-15878 | | Internal Fusion Loop (GP2) | | Prevents 6-helix bundle formation; blocks endosomal membrane fusion.[20] | | Broadly neutralizing across species; functions post-cleavage.[25] |

| ADI-23774 | | Prefusion Base | | Binds prefusion chalice; synergistic neutralization without competition.[20] | | Highly affinity-matured to ensure robust binding to Bundibugyo.[26] |

| MBP134AF Cocktail | | Dual-Target (Base + Fusion Loop) | | Afucosylated Fc region amplifies Antibody-Dependent Cellular Cytotoxicity.[21] | | Recruits Natural Killer cells to destroy infected host tissues.[26] |

| MBP431 Cocktail | | Dual-Target (Base + Fusion Loop) | | Extended half-life substitutions.[22] | | Allows for single-dose intramuscular injection, bypassing IV requirements.[22] |

Alongside remdesivir -- which shows higher in vitro potency against BDBV than Zaire ebolavirus, achieves up to 80 percent NHP survival when combined with monoclonals, and requires monitoring for the F548S polymerase resistance mutation -- vaccine countermeasures advanced rapidly into human trials in late 2026.[27][28][29][30][31] In October 2026, Oxford Vaccine Group's ChAdOx1 BDBV entered Phase 1 trials in the UK and Uganda while WHO and DRC's INRB added both ChAdOx1 BDBV and Moderna's mRNA-1469 candidate to the Tumaini Phase 2/3 ring-vaccination trial alongside rVSV-BDBV and multivalent mRNA ([GPs+NP]@LNP) platforms.[32][33][34][35]

| Vaccine Candidate | | Technological Platform | | Primary Developer / Manufacturing Partner | | Clinical Status (as of Nov 2026) |

| rVSV-BDBV | | Recombinant Vesicular Stomatitis Virus | | University of Texas Medical Branch / WHO | | NHP proof-of-concept; evaluated for Tumaini ring-vaccination platform.[32][33] |

| ChAdOx1 BDBV | | Chimpanzee Adenovirus Vector | | Oxford Vaccine Group / Serum Institute of India | | Entered Phase 1 trials (Oct 2026); added to Tumaini Phase 2/3 DRC trial.[32][33] |

| mRNA-1469 & [GPs+NP]@LNP | | mRNA Lipid Nanoparticle | | Moderna / Academic Consortia | | mRNA-1469 recommended for Tumaini Phase 2/3 trial; multivalent platform in preclinical testing.[33][34] |

Conclusion: Containment Realities and Continental Health Sovereignty

Ongoing control of the 2026 Bundibugyo emergency depends on biocontainment isolation, 21-day contact tracing, multiplexed PCR assays, and rapid cross-border surveillance -- strategies that successfully ended transmission in Uganda and prevented secondary spread in Kenya and Nigeria even as the DRC crisis continues.[1][2][7] Long-term resilience requires fulfilling the Africa CDC's goal of 60 percent domestic vaccine manufacturing by 2040 and prioritizing pan-ebolavirus countermeasures.[5][33]

Updates... (Nov 23, 2026): Updated cumulative DRC figures to 11,762 laboratory-confirmed cases, 5,775 deaths (~49.1% CFR), and 3,240 recoveries as of November 20, 2026 per NICD's November 23, 2026 surveillance update; consolidated prior Nov 15 and Nov 20, 2026 notes; removed the forbidden access date from Reference [23]; corrected Reference [25] volume/issue/pagination from 185(4), 584-586 to 185(6), 943-945; and upgraded 20 references to verified exact publication dates.

References & Primary Sources

* [1] European Centre for Disease Prevention and Control (ECDC) (Nov 17, 2026; updated Nov 20, 2026). Ebola disease: Multi-country outbreak 2026. https://www.ecdc.europa.eu/en/ebola-disease-multi-country-outbreak-2026

* [2] Council on Foreign Relations (May 22, 2026). A New Ebola Outbreak Spreads Through Conflict and a Weak U.S. Response. https://www.cfr.org/articles/a-new-ebola-outbreak-spreads-through-conflict-and-a-weak-u-s-response

* [3] Centers for Disease Control and Prevention (May 16, 2026; updated Nov 23, 2026). Ebola Outbreak: Current Situation. https://www.cdc.gov/ebola/situation-summary/index.html

* [4] Doctors Without Borders (MSF) (May 21, 2026). Bundibugyo virus: Why this Ebola disease outbreak is different. https://www.doctorswithoutborders.org/latest/bundibugyo-virus-why-ebola-disease-outbreak-different

* [5] The Guardian (May 17, 2026). WHO says Ebola outbreak in DRC and Uganda is 'emergency' of international concern. https://www.theguardian.com/world/2026/may/17/who-ebola-outbreak-congo-uganda-global-health-emergency

* [6] Centers for Disease Control and Prevention (May 19, 2026). Ebola Disease Outbreak in the Democratic Republic of the Congo and Uganda (HAN00530).

https://www.cdc.gov/han/php/notices/han00530.html

* [7] National Institute for Communicable Diseases (NICD) (May 18, 2026; updated Nov 23, 2026). Bundibugyo virus disease updates. https://www.nicd.ac.za/bundibugyo-virus-disease-updates/

* [8] World Health Organization (May 22, 2026). Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo (2026-DON603). https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON603

* [9] World Health Organization (May 17, 2026). Epidemic of Ebola Disease caused by Bundibugyo virus determined a PHEIC. https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determ

* [10] de La Vega, M.-A., Wong, G., Kobinger, G. P., & Qiu, X. (Feb 1, 2015). The Multiple Roles of sGP in Ebola Pathogenesis. Viral Immunology, 28(1), 3-9. -- https://doi.org/10.1089/vim.2014.0068

* [11] Feldmann, H., Sprecher, A., & Geisbert, T. W. (May 7, 2020). Ebola. New England Journal of Medicine, 382(19), 1832-1842. -- https://doi.org/10.1056/NEJMra1901594

* [12] Biedenkopf, N., Bukreyev, A., Chandran, K., et al. (Aug 3, 2023). Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae. Archives of Virology, 168, 220. -- https://doi.org/10.1007/s00705-023-05834-2

* [13] Zhu, W., Banadyga, L., Emeterio, K., & Wong, G. (Oct 31, 2019). The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development. Viruses, 11(11), 999. -- https://doi.org/10.3390/v11110999

* [14] Bornholdt, Z. A., Ndungo, E., Fusco, M. L., et al. (Mar 2, 2016). Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. mBio, 7(1), e02154-15. -- https://doi.org/10.1128/mbio.02154-15

* [15] Lee, J. E., & Saphire, E. O. (Nov 9, 2009). Ebolavirus glycoprotein structure and mechanism of entry. Future Virology, 4(6), 621-635. -- https://doi.org/10.2217/fvl.09.56

* [16] Sullivan, N. J., Martin, J. E., Graham, B. S., & Nabel, G. J. (Apr 16, 2009; print May 2009). Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nature Reviews Microbiology, 7, 393-400. -- https://doi.org/10.1038/nrmicro2129

* [17] Omara, S., Kiwuwa-Muyingo, P., Balinandi, S., et al. (Oct 18, 2021). Genetic Diversity of Bundibugyo Ebolavirus from Uganda and the Democratic Republic of Congo. bioRxiv. -- https://doi.org/10.1101/2021.10.18.464898

* [18] Levine, C. B., Mire, C. E., Geisbert, T. W., et al. (Aug 11, 2021; issue Sep 27, 2021). Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System. Journal of Virology, 95(17), e00643-21. -- https://doi.org/10.1128/jvi.00643-21

* [19] Johnson, J. / MSF UK (May 22, 2026). Explained: Why is this Ebola disease

outbreak different?
https://msf.org.uk/article/explained-why-ebola-disease-outbreak-different

* [20] Wirchnianski, A. S., Nyakatura, E. K., Herbert, A. S., et al. (Apr 11, 2024). Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies. PLOS Pathogens. -- https://doi.org/10.1371/journal.ppat.1012134

* [21] Murin, C. D., Gilchuk, P., Crowe, J. E., & Ward, A. B. (Jan 10, 2022). Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. Frontiers in Immunology, 12, 808047. -- https://doi.org/10.3389/fimmu.2021.808047

* [22] Kuang, E., Cross, R. W., McCavitt-Malvido, M., et al. (Jan 6, 2022). Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. bioRxiv. -- https://doi.org/10.1101/2022.01.06.475142

* [23] World Health Organization (WHO) (Jul 2, 2026). Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease. -- https://www.who.int/news/item/02-07-2026-patient-enrolment-begins-in-a-scientific-trial-to-identify-the-first-effective-treatments-fo

* [24] Shcherbakov, D., Isaeva, A., & Mustaev, A. (Mar 5, 2025). Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies. Antibodies, 14(1), 22. -- https://doi.org/10.3390/antib14010022

* [25] Anthony, S. M., & Hensley, L. E. (Mar 17, 2022). Cocktail party: Low-dose antibody combinations deliver pan-ebolavirus protection. Cell, 185(6), 943-945. -- https://doi.org/10.1016/j.cell.2022.01.025

* [26] Wec, A. Z., Bornholdt, Z. A., He, S., et al. (Aug 20, 2018). Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection. bioRxiv. -- https://doi.org/10.1101/395525

* [27] Carey, P. (May 22, 2026). Oxford scientists developing Ebola vaccine using Covid breakthrough. The National. https://www.thenationalnews.com/health/2026/05/22/oxford-scientists-developing-ebola-vaccine-using-covid-breakthrough/

* [28] Lo, M. K., Albari o, C. G., Perry, J. K., et al. (Oct 7, 2020; print Oct 27, 2020). Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. PNAS, 117(43), 26946-26954. -- https://doi.org/10.1073/pnas.2012294117

* [29] Gilead Sciences (Oct 8, 2025). Gilead Donates Remdesivir for Ebola Clinical Trial in the Democratic Republic of the Congo. https://www.gilead.com/company/company-statements/2025/gilead-donates-remdesivir-for-ebola-clinical-trial-in-the-democratic-rep

* [30] Cross, R. W., Bornholdt, Z. A., Prasad, A. N., et al. (May 23, 2022). Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight, 7(10), e159090. -- https://doi.org/10.1172/jci.insight.159090

* [31] KFGO / Reuters (May 21, 2026). Factbox-Bundibugyo Ebola vaccines and treatments in development.

https://kfgo.com/2026/05/21/factbox-bundibugyo-ebola-vaccines-and-treatments-in-development/

* [32] Gavi VaccinesWork (May 22, 2026). Bundibugyo, the rare virus causing a deadly new Ebola outbreak in DRC, has no vaccine yet. https://www.gavi.org/vaccineswork/bundibugyo-rare-virus-causing-deadly-new-ebola-outbreak-drc-has-no-vaccine-yet

* [33] Gavi VaccinesWork (Nov 10, 2026). Can two new vaccines help turn the tide against Bundibugyo Ebola? https://www.gavi.org/vaccineswork/can-two-new-vaccines-help-turn-tide-against-ebola-caused-bundibugyo-virus

* [34] Zhang, J., Zhang, X., Yao, Y., et al. (May 18, 2026; print May 26, 2026). Multivalent mRNA vaccine platform with compatible antigens conferred broad-spectrum protection against orthoebolaviruses' exposure. PNAS. -- https://doi.org/10.1073/pnas.2517814123

* [35] NIH Office of Technology Transfer (Jun 5, 2018). Novel Fourth Human Ebolavirus species, Bundibugyo ebolavirus. https://www.techtransfer.nih.gov/tech/tab-3267